Results 81 to 90 of about 19,821,917 (190)

Off-Label Use of Non-Vitamin K Antagonist Oral Anticoagulants

Journal of the American College of Cardiology, 2017
In their report, Steinberg et al. [(1)][1] nicely demonstrate that despite the advantage of uniform non-vitamin K antagonist oral anticoagulants (NOAC) dosing, off-label treatment occurs in approximately 13% of patients, which is related to adverse outcomes.
Vugt, S.P.G. van, Brouwer, M.A., Verheugt, F.W.A.   +2 more
openaire   +4 more sources

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Safety of Lowering the Platelet Transfusion Threshold Before Central Venous Catheterisation in Patients With Haematological Diseases

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Central venous catheter (CVC) insertion is frequently required in patients with haematological diseases. Despite limited evidence, thrombocytopenia often prompts prophylactic platelet transfusion before catheterisation. Methods We conducted an observational before‐and‐after study including the first non‐tunnelled CVC insertion ...
Mathias Lazarevic Lindblad, Elin Pålsson, Vladimir Lazarevic, Leila Naddi, Ola Borgquist, Lars Nilsson, Maria Adrian, Björn P. Bark, Thomas Kander   +8 more
wiley   +1 more source

Supplemental Material, sj-docx-1-cpt-10.1177_10742484211049919 - Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation

, 2021
Supplemental Material, sj-docx-1-cpt-10.1177_10742484211049919 for Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation by Susin Park and Nam Kyung Je in
Susin Park (11479394), Nam Kyung Je (5801678)   +1 more
core   +2 more sources

Cost-Effectiveness Of The Non-Vitamin K Antagonist Oral Anticoagulants For Atrial Fibrillation In Portugal [PDF]

Value in Health, 2015
Recently, three novel non-vitamin K antagonist oral anticoagulants received approval for reimbursement in Portugal for patients with non-valvular atrial fibrillation (AF). It is therefore important to evaluate the relative cost-effectiveness of these new oral anticoagulants in Portuguese AF patients.A Markov model was used to analyze disease ...
Costa, J, Fiorentino, F, Caldeira, D, Inês, M, Lopes Pereira, C, Pinheiro, L, Vaz-Carneiro, A, Borges, M, Gouveia, M   +8 more
openaire   +4 more sources

Do We Really Know How to Manage Anticoagulated Patients for Periodontal Nonsurgical Therapy? An Observational Cohort Study

International Journal of Dental Hygiene, EarlyView.
ABSTRACT Objectives The aim of this work is to assess and compare the impact of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKA) during and immediately after periodontal nonsurgical therapy. Materials and Methods A prospective observational cohort study was conducted with patients who presented a history of cardiovascular disease ...
F. Berton, A. Rapani, F. Costantinides, V. Nicolin, D. Cuhureanu, R. Di Lenarda   +5 more
wiley   +1 more source

Performance Assessment of Staclot‐LA Assay on Fully Automated Coagulation Analyser for Lupus Anticoagulant Testing Using Internal and External Quality Controls

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction It is recommended to detect lupus anticoagulant (LA) using two phospholipid‐dependent clotting assays, including a LA‐sensitive activated partial‐thromboplastin‐time (aPTT). Among these reagents, Staclot‐LA assay is performed on a mixture of test and normal plasma with and without hexagonal phase phospholipids.
V. Siguret, G. Jourdi, S. Melicine, L. Goubeau, Q. Pomorski, B. Joly‐Laffargue, A. Stepanian, M. Delrue, C. Bon, P. Meijer, E. Curis   +10 more
wiley   +1 more source

Left Atrial Appendage Thrombus in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation: Prevalence and Risk Factors

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Atrial fibrillation (AF) is common in hypertrophic cardiomyopathy (HCM) and increases stroke risk, primarily due to thromboembolism from the left atrial appendage (LAA). Oral anticoagulation (OAC) is recommended, but data on LAA thrombus (LAAT)
Leon Dinshaw, Benjamin Lippmann, Ruben Schleberger, Laura Rottner, Fabian Moser, Jannis Dickow, Paula Münkler, Marc D. Lemoine, Henrik Schneider, Bruno Reißmann, Feifan Ouyang, Andreas Metzner, Paulus Kirchhof, Monica Patten, Andreas Rillig   +14 more
doaj   +1 more source

New safety standards for anticoagulant therapy in the treatment of atrial fibrillation

Российский кардиологический журнал, 2018
The review article study the safety and efficacy of using direct acting oral anticoagulants: thrombin inhibitor dabigatran etexilate and inhibitors Xa of the blood clotting factor apixaban, rivaroxaban and edoxaban compared with the vitamin K antagonist ...
E. I. Baranova
doaj   +1 more source

Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia

Journal of Cardiovascular Pharmacology, 2018
Aims: Thrombocytopenia was one of the exclusion criteria in randomized trials in which non–vitamin K antagonist oral anticoagulants (NOACs) were tested. The safety of NOACs in patients with atrial fibrillation (AF) and thrombocytopenia remains unclear.
Janion-Sadowska, Agnieszka, Papuga-Szela, Elżbieta, Łukaszuk, Robert, Chrapek, Magdalena, Undas, Anetta   +4 more
openaire   +3 more sources